Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients – “En route for eradication”?

Pierre Pradat,C Migault,A Boibieux,M Porte,M Besnier,V Corbin,I Perbost,D Garipuy,F Ajana,J Koffi,S Gallie,A Frésard,I Jacquet,F Touam,Ch Allienne,H Laurichesse,Christine Jacomet,Jacques Reynes,M.A Valantin,A De Monte,H Melliez,M.J Soavi,E Ressiot,C Rouger,J Lippmann,David Rey,M Mularczyk,C Debreux,F Bozon,B Marchou,I Lepain,B Bonnet,S Casanova,P Morineau,M Ouka,Claudine Duvivier,D Lambert,I Alcaraz,M Valette,V Guéripel,P Dellamonica,L Larmet,E Puntis,N Viget,C Guglielminotti,B Rozé,I Schlienger,M.C Thiebaut-Drobacheff,Th Huleux,V Mondain,V Faucherre,C Lions,F Lucht,H Hüe,Laurent Cotte,S Vandame,J Durant,Thomas Huleux,J Cottalorda,F Biron,V Baclet,R Garraffo,M Marcel,I Lamaury,C Brochier,Lise Cuzin,C Auméran ,Dilek Çoban ,C Bernaud ,Vincent Gendrin ,Caroline Charlier ,Élisa Demonchy ,Marc‐Antoine Valantin ,S Degroodt ,Olivier Lesens ,C Ceppi ,T Jovelin ,Véronique Obry-Roguet ,Pierre Delobel ,Yohan N’guyen ,Guillaume Martin‐Blondel ,Agnés Meybeck ,Karine Sauné ,Élisabeth André-Garnier ,Antoine Chéret ,V Rio ,Georges Dos Santos ,Audrey Rodallec ,Maria Alvarez ,Corinne Brunet ,Jeanne‐Marie Jacquet ,Alexa Debard ,Solène Pineau ,Firouzé Bani‐Sadr ,Alain Makinson ,Fanny Lanternier ,Olivier Baud ,Laurence Fagour ,A S Ritleng ,Nazan Tuna Oran ,Marie-Laure Casanova ,A Ivanova ,Christophe Longuet ,Karine Risso ,Céline Cazorla ,C Louisin ,Sylvie Brégigeon ,Catherine Chirouze ,Sandrine Pierre-François ,P Point ,P Geneau De Lamarlière ,N Biezunski ,Isabelle Poizot‐Martin ,Anne Galinier ,Camille Fourcade ,M J Ducassou ,J G Fuzibet ,C Augustin-Normand ,Olivia Faucher ,Claire Rouzaud ,G Cessot ,Christine Cheneau ,Christian Chidiac ,E De Mautort ,Ana Montoya-Ferrer ,María Amparo Gómez Vidal ,Éric Cua ,Éric Billaud ,Rachida Ouissa ,J Berger ,Éric Rosenthal ,Rachid Agher ,Pascal Puglièse ,Delphine Lebrun ,Charlotte Biron ,Elisabeth Braun ,Patrick Miailhes ,Marie-Laure Batard ,Hélène Laroche ,Claudine Bernard-Henry ,Mathias Lutz ,Véronique Reliquet ,Thomas Perpoint ,Clotilde Allavena ,Corinne Merle De Boever ,Sylvie Abel ,Raymond Césaire ,M Orticoni ,Vincent Le Moing ,I Kmiec ,David Boutoille ,E Aïssi ,P M Roger ,Bruno Hoën ,Maria Paola Carta ,C Etienne ,Christine Katlama ,Nadine Atoui ,M Priester ,Élisabeth Botelho-Nevers ,David Lebeaux ,Patricia Fischer ,François Raffi ,A Foltzer ,Sylvie Pillet ,S Wehrlen-Pugliese ,P Choisy ,A Joulié ,Cyrille Delpierre ,M Partisani ,O Aubry ,Fatiha Najioullah ,Stephen J Ferrando ,Carla Blanco-Betancourt ,B Prouvost-Keller ,Sabelline Bouchez ,Tristan Ferry ,Amandine Gagneux‐Brunon ,Mathilde Pircher ,Olivier Lortholary ,Natacha Mrozek ,S Sausse ,Laurent Hustache‐Mathieu ,Johan Courjon ,Fatiha Daoud ,André Cabie ,Bonnie Henry ,Bertrand Riff ,Claire Aguilar ,Christina Psomas ,Paul‐Henri Consigny ,Anna Gergely ,Florence Ader ,Maxime Hentzien ,Alissa Naqvi ,Naomi M Hall

doi:10.1016/j.jinf.2017.05.008

Abstract

Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients. All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. Among 32,945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years.

Full Text